Introduction {#Sec1}
============

Diabetes is a global health problem, and although recent US trends suggest that the prevalence of diabetes has stabilized \[[@CR1]\], global projections indicate that the number of individuals with diabetes is set to grow substantially in the coming years \[[@CR2]\]. Globally, in 2015, 415 million adults aged 20--79 years had diabetes, and by 2040 that number is expected to increase to 642 million \[[@CR3]\]. Regional increases in diabetes prevalence of 19 to 141% are expected among adults in Europe (19%), North America and the Caribbean (37%), the Western Pacific (41%), South and Central America (65%), South-East Asia (79%), the Middle East and North Africa (104%), and Africa (141%) \[[@CR3]\]. The prevalence of diabetes is expected to increase across all income levels and age groups \[[@CR2]\].

The progressive nature of type 2 diabetes (T2D) \[[@CR4]\] necessitates the use of more than one glucose-lowering agent in many individuals with diabetes in order to achieve glycemic control \[[@CR5]\]. Current diabetes treatment guidelines recommend an individualized stepwise approach with sequential addition of single oral glucose-lowering agents for patients who do not achieve their glycemic goal within 3 months \[[@CR3], [@CR5], [@CR6]\]. The selection of a glucose-lowering agent should take into consideration numerous factors such as efficacy, potential side effects, weight profile, hypoglycemia risk, cost, patient preference, and comorbidities \[[@CR5], [@CR6]\]. Of these factors, comorbidities associated with diabetes such as hypercholesterolemia, hypertension, and obesity are associated with marked morbidity and mortality among patients \[[@CR7]\]. Among patients with T2D, the prevalence is ≥60% for each of elevated low-density lipoprotein (LDL), hypertension, and obesity \[[@CR7]\]. In addition to increased cardiovascular (CV) morbidity, CV disease (CVD) is a leading cause of death in patients with diabetes and accounts for \>50% of deaths in patients with T2D \[[@CR8]\]. Mortality from heart disease is 2--4 times greater for patients with T2D compared to patients without diabetes \[[@CR7]\]. The consequences of diabetes comorbidities are grave, yet the achievement of glycemic, blood pressure, and lipid treatment goals remains suboptimal in patients with T2D, especially in some minority groups (e.g., Mexican Americans and non-Hispanic blacks) \[[@CR9]\].

Intensive glucose control early in the course of T2D has been associated with reductions in microvascular complications \[[@CR10], [@CR11]\], and, over the long-term, risk reductions in some macrovascular complications have also been reported \[[@CR11], [@CR12]\]. The results of large CV outcomes trials for newer classes of glucose-lowering agents have shown a CV benefit (empagliflozin \[[@CR13]\], a sodium-glucose cotransporter-2 inhibitor; liraglutide \[[@CR14]\] and semaglutide \[[@CR15]\], glucagon-like peptide-1 (GLP-1) receptor agonists) or no increased CV risk (lixisenatide \[[@CR16]\], a GLP-1 receptor agonist; alogliptin \[[@CR17]\], sitagliptin \[[@CR18]\], and saxagliptin \[[@CR19]\], dipeptidyl peptidase-4 (DPP-4) inhibitors). Although no evidence of increased CV harm (neutral results for composite end points of major CV events and extended major CV events, including hospitalization for heart failure) has been observed, an increase in hospitalization for heart failure was observed in the CV outcomes trial for saxagliptin (the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes-Mellitus-Thombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) trial \[[@CR19]\]) and in patients without a history of heart failure in a separate post hoc subanalysis of the CV outcomes trial for alogliptin (Examination of CV Outcomes With Alogliptin Versus Standard Care \[[@CR17], [@CR20]\]).

Therapies that have favorable or neutral metabolic effects in addition to glucose-lowering properties are needed. Saxagliptin is an orally active, selective, and competitive DPP-4 inhibitor indicated for the treatment of T2D as an adjunct to diet and exercise to improve glycemic control \[[@CR21]\]. Inhibition of DPP-4 prevents the degradation of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), two gastrointestinal-derived hormones that play major roles in blood glucose control \[[@CR22]\]. In individual trials, saxagliptin has demonstrated efficacy and safety as a monotherapy and an add-on combination therapy in patients with T2D \[[@CR23]--[@CR29]\]. Additionally, saxagliptin demonstrated a favorable safety and tolerability profile in patients with T2D ≥65 years of age when saxagliptin was used as a monotherapy or add-on therapy \[[@CR30]--[@CR33]\]. A pooled analysis of 20 randomized controlled studies demonstrated the safety and tolerability of saxagliptin when used as a monotherapy or add-on therapy; however, this pooled analysis did not examine efficacy \[[@CR34]\]. The present paper reports a meta-analysis of data from 14 phase 2 and 3, double-blind, randomized, controlled trials that evaluated the efficacy of saxagliptin in relation to glycemic and metabolic end points in patients with T2D across treatment regimens.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This analysis included data from 14 phase 2 and 3, 12- and 24-week, double-blind, randomized, controlled studies (*N* = 4632) examining saxagliptin 5 mg/d (or 2.5 mg/d in individuals with moderate \[creatinine clearance 30 to \<50 mL/min\], severe \[creatinine clearance \<30 mL/min, not receiving dialysis\], or end-stage \[hemodialysis-dependent\] renal impairment) for the treatment of patients with T2D and inadequate glycemic control (Table [1](#Tab1){ref-type="table"}) \[[@CR23], [@CR24], [@CR26]--[@CR28], [@CR35]--[@CR43]\]. This analysis included 13 studies from the previously published pooled safety analysis \[[@CR34]\] and one more recent study. Seven studies used in the pooled safety analysis were excluded from our meta-analysis because they were either less than 12 weeks in duration, used an active comparator, or they used uptitration of metformin as a control. In the studies included in this meta-analysis, all procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki (1964). Informed consent was obtained from all patients before they were included in the studies.Table 1Trial characteristicsStudy identifierDesign^a^A1C inclusion criteria, %Patients in analysis, *n*CV181008 \[[@CR35]\]Monotherapy, treatment-naive^b^6.8--9.7104CV181011 \[[@CR24]\]Monotherapy, treatment-naive7.0--10.0195CV181038 \[[@CR23]\]Monotherapy, treatment-naive7.0--10.0137CV181063 \[[@CR36]\]Monotherapy, treatment-naive7.0--10.0551CV181082 \[[@CR37]\]Monotherapy, treatment-naive7.0--10.0209CV181057 \[[@CR38]\]Add-on to INS+MET7.5--11.0449CV181014 \[[@CR39]\]Add-on to MET7.0--10.0361CV181080 \[[@CR40]\]Add-on to MET^b,c^7.0--10.0158CV181064 \[[@CR41]\]Add-on to MET7.0--10.0554CV181117 \[[@CR26]\]Add-on to MET+SU7.0--10.0254CV181013 \[[@CR27]\]Add-on to TZD7.0--10.5363CV181040 \[[@CR42]\]Add-on to SU vs SU7.5--10.0514CV181039 \[[@CR28]\]Initial combination therapy vs monotherapy8.0--12.0619CV181062 \[[@CR43]\]Renal impairment, add-on to existing therapy^b,d^7.0--11.0164Total number of patients, *N*4638*A1C* glycated hemoglobin, *BID* twice daily, *INS* insulin, *MET* metformin, *SU* sulfonylurea, *TZD* thiazolidinedione^a^All trials were 24 weeks in duration and the dose of saxagliptin dose was 5 mg/d unless otherwise noted^b^Trial duration was 12 weeks^c^Saxagliptin dose was 2.5 mg BID^d^Saxagliptin dose was 2.5 mg/d

Outcome Measures {#Sec4}
----------------

The principal glycemic efficacy end points were mean change in glycated hemoglobin (A1C) from baseline and the percentage of patients achieving A1C targets of \<7% and ≤6.5%. Other glycemic end points that were assessed included mean change from baseline in fasting plasma glucose (FPG), insulin, C-peptide, and glucagon plasma concentrations; area under the curve (AUC) during an oral glucose test for postprandial glucose (PPG), insulin, C-peptide, and glucagon; and mean change from baseline in homeostasis model assessment of β-cell function (HOMA-2%β) and HOMA-2 insulin resistance (IR). Metabolic efficacy end points that were assessed included mean change from baseline in body weight, waist circumference, and body mass index (BMI); mean change from baseline in systolic and diastolic blood pressure; and mean percent change from baseline in fasting lipids (total cholesterol, LDL cholesterol, high-density lipoprotein \[HDL\] cholesterol, triglycerides, and free fatty acids).

Statistical Analysis {#Sec5}
--------------------

Baseline was defined as the last assessment on or before the date of the first dose of the double-blind study medication. The difference between saxagliptin and the comparator in change or percentage change from baseline mean (95% CI) for each study was determined using an analysis of covariance (ANCOVA) model with treatment group as an effect and baseline value as the covariate. The analyses were performed on the full analysis set, consisting of all randomized patients who had both a baseline and at least one postrandomization measurement included in the analysis. If no end-of-study measurement was available, the last available earlier postbaseline measurement (last observation carried forward, LOCF) method was applied. For patients who started rescue medication before the end of the study, their last postbaseline measurement taken before the date of the first dose of rescue medication was used (prior to rescue). When studies were pooled, the change from baseline mean (95% CI) difference between saxagliptin and control for all continuous data glycemic and metabolic end points was determined using Review Manager 5.3 software (RevMan, Cochrane, London, UK). For dichotomous data, the treatment differences in the proportions of patients achieving A1C targets of \<7 and ≤6.5% (expressed as percentages) for saxagliptin and control were determined using RevMan. Between-treatment differences in study endpoints were analyzed using a random effects method where the weight assigned to each study was the inverse of the variance of the effect estimate. Thus, in general, larger studies were given more weight than smaller studies.

Results {#Sec6}
=======

Study Characteristics {#Sec7}
---------------------

This analysis included 14 phase 2 or 3 studies (Table [1](#Tab1){ref-type="table"}) that evaluated saxagliptin 5 mg/d or control as either monotherapy (*n* = 1196; 5 studies), add-on therapy (*n* = 2139 vs placebo and *n* = 514 vs uptitrated sulfonylurea; 6 studies and 1 study, respectively), or initial combination therapy (*n* = 619 vs control monotherapy; 1 study); or, for patients with renal impairment, saxagliptin 2.5 mg/d or placebo (*n* = 164; 1 study). All studies were 12 or 24 weeks in duration. Data from all 14 trials were included in the analysis of change from baseline in A1C; availability of data per study varied for all other end points.

Mean (SD) baseline A1C levels for saxagliptin and control were 8.12% (0.9%) and 8.07% (0.9%) for monotherapy versus placebo, 8.26% (1.0%) and 8.15% (0.9%) for add-on versus placebo, 8.26% (0.8%) and 8.15% (0.9%) for add-on versus uptitrated sulfonylurea, 9.41% (1.3%) and 9.43% (1.3%) for initial combination therapy versus control monotherapy, and 8.45% (1.2%) and 8.09% (1.1%) for saxagliptin versus placebo in patients with renal impairment (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Mean treatment difference in change in A1C from baseline across treatment regimens. *A1C* glycated hemoglobin, *CTL* control, *INS* insulin, *IV* inverse variance, *MET* metformin, *SAXA* saxagliptin, *SU* sulfonylurea, *TZD* thiazolidinedione

Glycemic Outcomes {#Sec8}
-----------------

For all 14 studies combined, the reduction from baseline in A1C was greater with saxagliptin versus control (mean treatment difference \[95% CI\] --0.55% \[--0.63%, --0.47%\]; Fig. [1](#Fig1){ref-type="fig"}). Large reductions in A1C were observed whether saxagliptin was used as a monotherapy versus placebo (--0.52% \[--0.63%, --0.40%\]; 5 studies) or as an add-on versus placebo (--0.55% \[--0.69%, --0.40%\]; 6 studies). Marked reductions in A1C from baseline were also observed whether saxagliptin was used as an add-on versus uptitrated sulfonylurea (--0.72% \[--0.88%, --0.56%\]; 1 study) or as an initial combination therapy versus control monotherapy (--0.54% \[--0.73%, --0.35%\]; 1 study). Large reductions in A1C with saxagliptin versus placebo were also noted in patients with renal impairment (--0.42% \[--0.75%, --0.09%\]; 1 study). Similar treatment effects were observed across subgroups of age, sex, and geographical region (Figs. S1--S3 in the Electronic supplementary material, ESM). Reductions from baseline in A1C favored saxagliptin versus control for patients \<65 years of age (--0.55% \[--0.67%, --0.43%\]; 9 studies), patients ≥65 years of age (0.54% \[--0.69% \[--0.69%, --0.38%\]; 10 studies), men (--0.54% \[--0.69%, --0.40%\]; 10 studies), and women (--0.55% \[--0.64%, --0.47%\]; 10 studies). The A1C reduction from baseline was generally similar across geographical regions of North America, Europe, Latin America, and Asia. A smaller reduction from baseline in A1C was observed for Africa; however, data were limited to a single add-on to insulin trial.

Across the combined studies, patients treated with saxagliptin were more likely to achieve A1C \<7% (39% vs 23%; treatment difference \[95% CI\] 0.16 \[0.13, 0.19\]; 13 studies) and A1C ≤6.5% (24% vs 14%; treatment difference \[95% CI\] 0.10 \[0.07, 0.13\]; 10 studies) versus control, with similar effects obtained when saxagliptin was used as a monotherapy or add-on therapy (Fig. [2](#Fig2){ref-type="fig"}a, b). The percentage of patients achieving A1C \<7% was greater with saxagliptin whether it was used as a monotherapy versus placebo (40% vs 25%), an add-on versus placebo (36% vs 21%), an add-on versus uptitrated sulfonylurea (23% vs 9.1%), or as initial combination therapy versus control monotherapy (60% vs 41%). Similarly, the percentage of patients achieving A1C ≤6.5% was greater with saxagliptin monotherapy versus placebo (22% vs 14%), add-on versus placebo (22% vs 10%), add-on versus uptitrated sulfonylurea (10% vs 4.5%), and initial combination therapy versus control monotherapy (45% vs 29%). Fig. 2Percentages of patients who achieved **a** A1C \<7% and **b** A1C ≤6.5%. *CTL* control, *INS* insulin, *IV* inverse variance, *MET* metformin, *SAXA* saxagliptin, *SU* sulfonylurea, *TZD* thiazolidinedione

The reduction from baseline in FPG was greater with saxagliptin versus control across the combined studies (mean treatment difference \[95% CI\] --12.89 mg/dL \[--15.82, --9.97\]; 13 studies, Table [2](#Tab2){ref-type="table"}). Likewise, a greater reduction from baseline in PPG AUC was observed with saxagliptin versus control across 10 studies (mean treatment difference \[95% CI\] --4.67 g min/dL \[--6.03, --3.30\]; Table [2](#Tab2){ref-type="table"}).Table 2Effect estimates for mean treatment differences in glycemic efficacy end-point changes from baseline for saxagliptin versus control in adults with T2DOutcomeBaseline saxagliptinSaxagliptin, *n*Baseline controlControl, *n*Studies, *n*Mean treatment difference^a^ IV, random95% CIFPG, mg/dL170.652319170.09218813--12.89--15.82, --9.97PPG AUC, g min/dL46,370123546,684106810--4.67--6.03, --3.30Fasting insulin, uU/mL11.74186711.66183911--0.15--0.65, 0.35Insulin AUC, mU min/mL5576.78385783.280981.140.65, 1.63Fasting C-peptide, ng/mL2.8718592.92170810--0.01--0.09, 0.06C-peptide AUC, ng min/mL936.5942936.9822882.2333.73, 130.74Glucagon, pg/mL73.66174771.65159710--2.22--3.92, --0.52Glucagon AUC, ng min/mL14,896103514,5648608--0.93--1.28, --0.58HOMA-2%β, %61.41169960.781640107.555.32, 9.78HOMA-2 IR, %3.1711093.1810997--0.14--0.24, --0.04*AUC* area under the curve, *FPG* fasting plasma glucose, *HOMA* homeostasis model assessment of β-cell function, *IR* insulin resistance, *IV* inverse variance, *PPG* postprandial glucose; T2D type 2 diabetes^a^Mean treatment difference in change from baseline for saxagliptin versus control

No difference was observed for change from baseline in fasting insulin between saxagliptin versus control (mean treatment difference \[95% CI\] --0.15 μU/mL \[--0.65, 0.35\]; 11 studies), whereas there was a modest increase from baseline in insulin AUC with saxagliptin versus control (mean treatment difference \[95% CI\] 1.14 mU min/mL \[0.65, 1.63\]; 8 studies, Table [2](#Tab2){ref-type="table"}). Results for C-peptide paralleled those observed for insulin, with no clinically meaningful differences observed for change from baseline in fasting C-peptide and an increase from baseline in C-peptide AUC with saxagliptin versus control.

The reduction from baseline in fasting glucagon was greater with saxagliptin versus placebo across 10 studies combined (mean treatment difference \[95% CI\] --2.22 pg/mL \[--3.92, --0.52\]). Similarly, a greater reduction from baseline in glucagon AUC was observed with saxagliptin versus control across eight studies (mean treatment difference \[95% CI\] --0.93 ng min/mL \[--1.28, --0.58\], Table [2](#Tab2){ref-type="table"}).

β-Cell function, calculated via the change from baseline in HOMA-2%β, improved with saxagliptin versus control (mean treatment difference \[95% CI\] 7.55% \[5.32%, 9.78%\]; 10 studies). The change from baseline in HOMA-2 IR indicated a slight reduction in insulin resistance with saxagliptin versus control (mean treatment difference \[95% CI\] --0.14% \[--0.24%, --0.04%\]; 7 studies, Table [2](#Tab2){ref-type="table"}).

Metabolic (Weight, Blood Pressure, and Lipid) Outcomes {#Sec9}
------------------------------------------------------

No clinically meaningful effects were observed for change from baseline in body weight (mean treatment difference \[95% CI\] 0.39 \[0.14, 0.64\] kg; 12 studies), waist circumference (0.31 \[--0.06, 0.69\] cm; 11 studies), or BMI (0.17 \[0.06, 0.28\] kg/m^2^; 11 studies) with saxagliptin versus control (Table [3](#Tab3){ref-type="table"}). Changes from baseline in systolic (mean treatment difference \[95% CI\] --0.19 \[--1.07, 0.68\] mmHg; 14 studies) and diastolic (0.09 \[--0.45, 0.64\] mmHg; 14 studies) blood pressure were similar with saxagliptin and control (Table [3](#Tab3){ref-type="table"}).Table 3Total effect estimates for mean treatment differences in weight and blood pressure end-point changes from baseline for saxagliptin versus control in adults with T2DParameterBaseline saxagliptinSaxagliptin, *n*Baseline controlControl, *n*Studies, *n*Mean treatment difference^a^ IV, random95% CIBody weight, kg79.64219578.932064120.390.14, 0.64Waist circumference, cm97.06172097.931727110.31--0.06, 0.69BMI, kg/m^2^29.31212129.031980110.170.06, 0.28Blood pressure Systolic, mmHg128.81934129.1172014--0.19--1.07, 0.68 Diastolic, mmHg79.3193479.41720140.09--0.45, 0.64*IV* inverse variance, *T2D* type 2 diabetes^a^Mean treatment difference in change from baseline for saxagliptin versus control

Modest reductions in percentage change from baseline in total cholesterol (mean treatment difference \[95% CI\] --1.47% \[--2.62%, --0.33%\]; 10 studies), HDL cholesterol (--1.74%, --2.92%, --0.57%\]; 10 studies), and fasting triglycerides (--4.08% \[--7.30% to --0.85%\]; 10 studies) were observed, along with tendencies for small reductions in LDL cholesterol (--0.73% \[--2.75% to 1.29%\]; 10 studies) and free fatty acid (--2.53% \[--8.19% to 3.13%\]; 7 studies) with saxagliptin versus control (Table [4](#Tab4){ref-type="table"}).Table 4Total effect estimates for mean treatment differences in lipid end-point percentage changes from baseline for saxagliptin versus control in adults with T2DParameterBaseline saxagliptinSaxagliptin, *n*Baseline controlControl, *n*Studies, *n*Mean treatment difference^a^ IV, random95% CITotal cholesterol, mg/dL194.651617194.41161610--1.47--2.62, --0.33LDL cholesterol, mg/dL112.981471112.88147310--0.73--2.75, 1.29HDL cholesterol, mg/dL45.36161644.71161610--1.74--2.92, --0.57Fasting triglycerides, mg/dL192.751617201.80161510--4.08--7.30, --0.85Free fatty acids, mg/dL0.539570.549627--2.53--8.19, 3.13*HDL* high-density lipoprotein, *IV* inverse variance, *LDL* low-density lipoprotein, *T2D* type-2 diabetes^a^Mean treatment difference in percentage change from baseline for saxagliptin versus control

Discussion {#Sec10}
==========

These analyses demonstrate that the efficacy of saxagliptin is consistent, whether given as a monotherapy, add-on therapy, or initial combination therapy. The effects are likewise consistent in patients with renal impairment, regardless of age and sex, and in different geographic regions. Patients with T2D were more likely to achieve therapeutic glycemic goals of either A1C \<7% or ≤6.5% with saxagliptin than with controls. Patients experienced greater mean reductions in A1C, FPG, PPG, and glucagon, as well as greater mean increases in postprandial insulin secretion and C-peptide levels. There were improvements in β-cell function as assessed by HOMA-2%β.

Saxagliptin prevents the degradation of incretins by inhibiting DPP-4. Incretins play a major role in glucose control, with as much as 70% of postprandial insulin secretion mediated by the incretins GIP and GLP-1 \[[@CR44]\]. After eating, patients experience a rapid and transient increase in GIP and GLP-1, with degradation by DPP-4 within minutes of secretion \[[@CR45]--[@CR47]\]. Saxagliptin at doses of 2.5--400 mg inhibits plasma DPP-4 activity by 50--79% at 24 h \[[@CR48]\]. Consequently, at the recommended dose of 5 mg/d in patients with T2D, GIP and GLP-1 concentrations are at least twofold more than baseline \[[@CR48], [@CR49]\]. The incretin effects of saxagliptin have been demonstrated as improvements in FPG, PPG, and glucose disposal through a combination of increased fasting and postprandial insulin secretion and a reduction in postprandial glucagon secretion in patients with T2D \[[@CR49]\]. Our analysis demonstrated an increase in insulin AUC and C-peptide AUC and reductions in fasting and postprandial glucagon secretion. Although we did not see an increase in fasting insulin or fasting C-peptide, treatment with saxagliptin was associated with significant reductions in both FPG and PPG.

In addition to improving glucoregulatory hormonal secretion, DPP-4 inhibition may also be associated with protective and/or restorative effects on β-cell function. Preclinical studies using a high-fat diet-fed, streptozotocin-induced mouse model of diabetes have shown that saxagliptin has beneficial effects on β-cell mass and islet cell morphology \[[@CR50]\], with clinical studies also demonstrating small positive effects on β-cell function. After a median 2-year follow-up, treatment with saxagliptin was associated with preservation of β-cell function, assessed by HOMA-2%β, whereas treatment with placebo was associated with a decline in β-cell function in patients with a history of T2D and CVD who participated in the SAVOR-TIMI 53 trial (*N* = 16,492) \[[@CR19], [@CR51]\]. These positive effects on pancreatic β-cells may explain the small improvements in HOMA-2%β observed in this study.

The results presented here are similar to a meta-analysis of 16 randomized, controlled studies ≥12 weeks in duration that examined the efficacy of DPP-4 inhibitors, including saxagliptin, compared with placebo in adults with T2D \[[@CR52]\]. The reduction from baseline in A1C was greater with DPP-4 inhibitors versus placebo (weighted mean difference \[95% CI\] --0.74% \[--0.85%, --0.62%\]; 16 studies), with similar efficacies observed when used as a monotherapy or add-on therapy \[[@CR52]\]. The magnitude of A1C reduction in the current analysis with saxagliptin (--0.55% \[ --0.63%, --0.47%\]) was slightly lower than that obtained with either vildagliptin (--0.73% \[--0.94%, --0.52%\]; 9 studies) or sitagliptin (--0.74% \[--0.84%, --0.63%\]; 7 studies), but this may be explained by differences in clinical study design, such as baseline A1C, T2D duration, concomitant glucose-lowering agents, study duration, run-in period, and washout \[[@CR52]\]. Similar to the analyses reported here for saxagliptin, a greater percentage of patients achieved A1C \<7% (43% vs 17%; 9 studies) and there was a greater reduction in FPG (weighted mean difference, --18 \[--22, --14\] mg/dL; 15 studies) with DPP-4 inhibitors versus placebo. Neutral effects of DPP-4 inhibitors versus placebo on nonglycemic parameters such as body weight and lipids were also observed \[[@CR52]\]. These neutral effects on weight and lipids are consistent with our meta-analysis. Weight neutrality is a desirable attribute for a glucose-lowering agent, given the association of obesity with CVD morbidity and mortality.

In addition to efficacy, the safety and risk--benefit profiles of glucose-lowering agents are important considerations when selecting appropriate therapies for patients. This report does not include a safety analysis because a previously published pooled analysis of 20 randomized controlled studies, including 13 of the studies in the current meta-analysis, demonstrated the safety and tolerability of saxagliptin when used as a monotherapy or add-on therapy \[[@CR34]\]. Analysis of these 20 studies found that the incidence rates (per 100 patient-years) of serious adverse events (saxagliptin, 7.3; control, 7.2) and discontinuations due to adverse events (saxagliptin, 4.2; control, 3.9) with saxigliptin were similar to those obtained with the control, and were consistent irrespective of age and sex. Compared with the controls, premature discontinuation rates with saxagliptin were similar in eight studies, higher in three studies, and lower in nine studies \[[@CR34]\].

The limitations of our analyses are the small number of studies in some treatment regimens and the inclusion of only a single study for some treatment regimen categories. Because these analyses were limited to studies 12 or 24 weeks in duration, the durability of the efficacy of saxagliptin could not be evaluated. However, the long-term efficacy of saxagliptin was demonstrated previously \[[@CR53]\]. Although we recognize these limitations, our study has several strengths. Its large size is representative of a heterogeneous patient population, and the included studies were randomized, double-blind, placebo- or active-controlled studies. The inclusion of a broad patient population allowed for subgroup analysis, which demonstrated the efficacy of saxagliptin across subgroups defined by age, sex, or geographical location.

Conclusion {#Sec11}
==========

Improving glycemic control is of the utmost importance when attempting to slow the progression of T2D and prevent microvascular complications. Thus, glucose-lowering agents such as saxagliptin with glycemic efficacy, a low risk for hypoglycemia, and neutral effects on metabolic end points are advantageous. The consistency of saxagliptin efficacy in different patient subgroups with T2D and across treatment regimens, as shown here, demonstrates its usefulness in a broad range of treatment settings.
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